Fluid collection from the lungs presents a potential cancer concern for smokers or previous cancer patients. While the anxiety associated with this prospect may be justified, the fact is that pleural effusion can have many causes unrelated to cancer. Therefore, it is important to understand what causes pleural effusions, how these conditions are diagnosed, and when they are related to cancer in order to help those suffering from them cope with the news.
The pleural space exists between two layers of membranes surrounding the lungs. Typically, there is only a minor amount of fluid in the pleural cavity, but when the volume of fluid increases beyond the normal range, the condition is identified as pleural effusion.An excessive fluid build-up may occur due to increased fluid creation or poor drainage. A number of conditions might affect either of these processes, so identifying the main process is of utmost importance for identifying the cause of the condition.
The majority of pleural effusions in the general population are not caused by cancer. The most common causes include:
In the case of a pleural effusion caused by cancer, it is termed malignant pleural effusion. It usually occurs when cancer cells invade the pleura, affecting fluid absorption and leading to fluid formation faster than it can be cleared. The common type of cancer associated with it is non-small cell lung cancer, which comprises around one-third of the total cases. Other types of cancers that follow are breast cancers and lymphomas.
The examination starts with imaging. Pneumonia can be diagnosed with chest X-rays, while ultrasound scans can assist with both localisation and drainage of fluid. Chest CT scans are used to examine the lungs, look for masses or swollen lymph nodes, and identify thickening or nodular patterns that indicate malignancy.Thoracentesis is a procedure in which a needle is inserted into the pleural space to collect fluid for various tests, including biochemical, cytological, and microbiological tests. If malignant cells are found, a biopsy and molecular testing can be done to confirm the diagnosis.
When the occurrence of malignant pleural effusion is due to lung cancer, the systemic use of a targeted medication is possible if molecular tests show the presence of a mutation in the tumor tissue that makes it suitable for specific treatment.Osimertinib is a third-generation inhibitor of tyrosine kinase receptor EGFR approved for the treatment of patients with lung cancer with a mutation in EGFR. As shown by the FLAURA study, patients treated with osimertinib have better survival data than patients treated with first-generation inhibitors of tyrosine kinase receptors. Thus, when lung cancer patients with malignant pleural effusion receive treatment, experiencing a decrease in the cancer burden, pleural effusion can significantly decrease or resolve, so breathlessness syndrome is reduced.Tagrisso 80mg Tablet is the standard maintenance dose formulation of osimertinib, taken orally once daily without regard to meals, under the supervision of a medical oncologist with regular clinical review and imaging to assess treatment response. It is associated with excellent tolerability compared to chemotherapy, with the most commonly reported effects including mild rash, diarrhoea, dry skin, and nail changes.
In cases where pleural effusion causes severe difficulty in breathing, draining the fluid relieves the symptoms until the cause is treated or identified. Therapeutic thoracentesis is the procedure that uses a needle or a small tube to aspirate the fluid. For persons with recurrent malignant pleural effusions, pleurodesis or an indwelling pleural catheter are good options for long-term management.
The side effects experienced by patients receiving targeted therapy for lung carcinoma differ significantly from those of traditional chemotherapy. It has been documented that changes in the skin and nails are among the most frequently experienced adverse effects of this type of treatment. Some patients also experience side effects such as diarrhea and loss of appetite. Interstitial lung disease is a rare adverse effect of targeted lung cancer therapy, which requires close monitoring of the patient for respiratory issues.
Realising that fluid has been found around the lungs during a scan or evaluation of new symptoms such as shortness of breath can be a traumatic experience for lung cancer patients. If cancer is found during the examination, it adds emotional strain to the situation regardless of the degree of treatability of the disease. It is essential to provide clear and compassionate information to patients regarding the test results, next steps to be undertaken, and what to expect during the treatment.
Post-treatment follow-up is conducted to evaluate the treatment’s effectiveness and monitor the presence of any pleural effusion. With respect to patients diagnosed with lung cancer caused by mutations in the EGFR gene who are being treated with targeted therapy, follow-up and evaluation of the effects of the treatment are usually carried out through CT imaging taken on a regular basis every 8 to 12 weeks.
In adults, pleural effusion may not be manifested as cancerous fluids leading to a cancer diagnosis. Moreover, the same investigations and treatments would differentiate between how pleural effusion would affect patients’ health condition and future prognosis. Thus, the correct actions include proper identification of the cause, assessment of the molecular markers present as soon as the lung cancer is confirmed, and commencement of treatment based on the data obtained.
Disclaimer: This article is for general informational purposes only and should not be considered medical advice. Always consult a qualified pulmonologist or oncologist for diagnosis, treatment, and guidance specific to your condition.